They are made by different companies (Innovent Biologics and Eli Lilly, respectively), have different clinical trial programs, and produce different levels of weight loss
In the United States, the Ozempic label covers three type 2 diabetes indications with no weight-management indication, while the Wegovy label carries the weight-management, cardiovascular and liver indications
Because of its significant negative impact on almost all body systems, obesity increases the risks of several other chronic diseases, including diabetes, heart disease, kidney disease, and cancer
Both mechanisms appear to become effective early after treatment initiation, with glycosuria continuing in the long term without any significant fluid change
Atrial fibrillation is usually more common in older people, However, people of any age group with risk factors such as hypertension, heart disease, diabetes, obesity can also develop atrial fibrillation